EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates

Zhuoliang Hu, Yuheng Liao, Mengxian Niu, Zhanghong Kong, Hugo Vankelecom, Jianjun Cheng, Michela Deleidi, Chenzhong Li, Zhengjin Jiang, Sumin Bian, Qiqin Wang

Acta Pharmaceutica Sinica B · 2026-09 · 16 (9) · 5509-5539

DOI: 10.1016/j.apsb.2026.05.032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-09. Verfasst von Zhuoliang Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 254 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, Guangzhou Science and Technology Program Key Projects, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid evolution of antibody‒drug conjugates (ADCs) and emerging X-drug conjugates (XDCs) has revolutionized targeted cancer therapy, yet their clinical translation is severely bottlenecked by the lack of human-relevant preclinical models. To bridge this translational gap, patient-derived organoids and organoids-on-chip (OoC) platforms recapitulate key features of human tumor biology, offering powerful tools for investigating cancer heterogeneity and improving the predictive evaluation of bioconjugated therapeutics. In this review, we systematically summarize the current landscape and challenges of ADCs and XDCs development across existing preclinical models, critically discuss the concepts, biological principles and application potential of organoid- and OoC-based systems, and highlight recent global policy developments and collaborative initiatives shaping their translational implementation. Finally, we highlight key challenges and future perspectives for leveraging organoids and OoCs in the druggability assessment, optimization, and translational development of ADCs and XDCs.

Schlagwörter

Stichwörter der Autor:innen

Antibody‒drug conjugatesDruggability assessment and drug screeningOrganoidsOrganoids-on-chipTargeted therapiesX-drug conjugates

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs/Institute of Pharmaceutical Analysi…
  • Laboratory of Tissue Plasticity in Health and Disease, Cluster of Stem Cell and Developmental Biology, Department of Development and Regeneration, KU Leuven, Leuven 3000, Belgium.
  • School of Engineering, Westlake University, Hangzhou 310024, China.
  • Imagine Institut, INSERM U1163, Paris Cite University, Paris 75015, France.
  • Department of Biomedical Engineering, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China.

Förderung

  • Natural Science Foundation of Guangdong Province
  • Guangzhou Science and Technology Program Key Projects
  • Fundamental Research Funds for the Central Universities
  • K. C. Wong Education Foundation
  • Guangzhou Municipal Science and Technology Project
  • High-end Foreign Experts Recruitment Plan of China
  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Hu, Z., Liao, Y., Niu, M., Kong, Z., Vankelecom, H., Cheng, J., Deleidi, M., Li, C., Jiang, Z., Bian, S., & Wang, Q. (2026). Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates. Acta Pharmaceutica Sinica B, 16(9), 5509-5539. https://doi.org/10.1016/j.apsb.2026.05.032

Vancouver

Hu Z, Liao Y, Niu M, Kong Z, Vankelecom H, Cheng J, et al. Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates. Acta Pharmaceutica Sinica B. 2026;16(9):5509-5539. doi:10.1016/j.apsb.2026.05.032

BibTeX
@article{Hu2026,
  author = {Hu, Zhuoliang and Liao, Yuheng and Niu, Mengxian and Kong, Zhanghong and Vankelecom, Hugo and Cheng, Jianjun and Deleidi, Michela and Li, Chenzhong and Jiang, Zhengjin and Bian, Sumin and Wang, Qiqin},
  title = {Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {9},
  pages = {5509--5539},
  doi = {10.1016/j.apsb.2026.05.032}
}
Kostenlos starten →